Massimo Massaia, MD, Santa Croce e Carle di Cuneo Hospital, Cuneo, Italy, briefly discusses the importance of measurable residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL) who have high-risk cytogenetics, and further comments on where MRD may fit into clinical practice in the future and the need for more studies in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.